Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.
Virchows Arch. 2023 Sep;483(3):299-316. doi: 10.1007/s00428-023-03599-2. Epub 2023 Aug 9.
The 2022 European Association for Haematopathology/Society for Hematopathology lymphoma workshop session on cavity-based lymphomas included sixty-eight cases in seven sections. The disease entities discussed include primary effusion lymphomas (PEL), extracavitary primary effusion lymphomas and confounding entities (ECPEL), HHV8-negative B-lineage lymphomas-effusion based (EBV-negative, EBV-positive, and plasmablastic types), diffuse large B-cell lymphoma associated with chronic inflammation, fibrin-associated diffuse large B-cell lymphoma (FA-DLBCL), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and other lymphomas presenting as an effusion. All entities above are discussed; however, three are delved into greater detail given the challenges with classification: ECPEL, HHV8-negative effusion-based lymphomas, and FA-DLBCL. Cases exemplifying the diagnostic difficulty in differentiating ECPEL from HHV8-positive diffuse large B-cell lymphoma and germinotropic lymphoproliferative disorder were discussed. The more recently recognized effusion-based HHV8-negative large B-cell lymphoma is explored, with several cases submitted raising the question if this subset should be carved out as a specific entity, and if so, what should be the refining diagnostic criteria. Case submissions to the FA-DLBCL section yielded one of the largest case series to date, including classic cases, cases furthering the discussion on disease sites and prognosis, as well as novel concepts to be considered in this entity. The 2022 EA4HP/SH workshop cases allowed for further confirmation of the characteristics of some of the more historically accepted cavity-based lymphomas, as well as further inquiry and debate on relatively new or evolving entities.
2022 年欧洲血液病理学协会/血液病理学协会淋巴瘤工作组关于腔隙性淋巴瘤的会议包括七个部分的 68 例病例。讨论的疾病实体包括原发性渗出性淋巴瘤（PEL）、腔外原发性渗出性淋巴瘤和混淆实体（ECPEL）、HHV8 阴性 B 细胞淋巴瘤-渗出液为基础（EBV 阴性、EBV 阳性和浆母细胞型）、伴有慢性炎症的弥漫性大 B 细胞淋巴瘤、纤维蛋白相关弥漫性大 B 细胞淋巴瘤（FA-DLBCL）、乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）和其他以渗出液为表现的淋巴瘤。所有上述实体都进行了讨论；然而，由于分类方面的挑战，有三个实体进行了更详细的探讨：ECPEL、HHV8 阴性渗出液性淋巴瘤和 FA-DLBCL。讨论了举例说明在区分 ECPEL 与 HHV8 阳性弥漫性大 B 细胞淋巴瘤和生殖细胞性淋巴增生障碍方面的诊断困难的病例。探讨了最近认识到的以渗出液为基础的 HHV8 阴性大 B 细胞淋巴瘤，提交了多个病例，提出了这个亚组是否应该作为一个特定的实体分离出来的问题，如果是这样，应该制定什么样的细化诊断标准。提交给 FA-DLBCL 部分的病例提供了迄今为止最大的病例系列之一，包括经典病例、进一步讨论疾病部位和预后的病例，以及在该实体中需要考虑的新概念。2022 年 EA4HP/SH 工作组的病例进一步证实了一些历史上更被接受的腔隙性淋巴瘤的特征，以及对相对较新或正在发展的实体进行进一步的询问和辩论。
